Lee Ga-young showed his senior's true face to the spirited 19-year-old rookie.Lee Ga-young lifted the trophy after a neck-and ...

Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...

We are initiating coverage of biosimilar manufacturer Celltrion. Its current flagship drugs include biosimilars to Remicade, Rituxan, Herceptin, and Avastin. The bottom line: We initiate with a ...

INCHEON, South Korea, February 19, 2025--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

TORONTO, March 27, 2025--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...

Celltrion has finally merged with Celltrion Healthcare, three years after its original plan was announced. Celltrion announced that its board had approved the merger on Thursday. Each share of ...

Celltrion's fourth-quarter net profit plunged 99.4 percent on year on the back of sluggish sales of biosimilars. Net profit came to 453 million won ($340,218) in the last three months of 2023, a ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...